BlackRock
DFTX

BlackRock’s Definium Therapeutics DFTX Stock Holding History

BlackRock’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$160M Buy
8,480,230
+206,954
+3% +$3.51M ﹤0.01% 1803
2025
Q4 		$111M Buy
8,273,276
+2,337,719
+39% +$28.9M ﹤0.01% 2046
2025
Q3 		$70M Buy
5,935,557
+133,418
+2% +$1.24M ﹤0.01% 2299
2025
Q2 		$37.7M Buy
5,802,139
+86,426
+2% +$568K ﹤0.01% 2624
2025
Q1 		$33.4M Sell
5,715,713
-354,340
-6% -$2.54M ﹤0.01% 2609
2024
Q4 		$42.2M Buy
6,070,053
+406,020
+7% +$2.79M ﹤0.01% 2562
2024
Q3 		$32.2M Buy
5,664,033
+280,003
+5% +$1.95M ﹤0.01% 2734
2024
Q2 		$38.8M Buy
5,384,030
+4,589,718
+578% +$40.1M ﹤0.01% 2574
2024
Q1 		$7.47M Buy
794,312
+243,695
+44% +$1.39M ﹤0.01% 3501
2023
Q4 		$2.02M Buy
550,617
+1,536
+0.3% +$4.63K ﹤0.01% 4037
2023
Q3 		$1.72M Sell
549,081
-4,231
-0.8% -$17.4K ﹤0.01% 4058
2023
Q2 		$1.98M Buy
553,312
+101,320
+22% +$350K ﹤0.01% 4057
2023
Q1 		$1.43M Hold
451,992
– – ﹤0.01% 4203
2022
Q4 		$994K Buy
451,992
+421,478
+1,381% +$1.17M ﹤0.01% 4414
2022
Q3 		$107K Buy
30,514
+16,641
+120% +$160K ﹤0.01% 5158
2022
Q2 		$133K Sell
13,873
-1,081,741
-99% -$13.7M ﹤0.01% 5150
2022
Q1 		$18.2M Sell
1,095,614
-42,091
-4% -$730K ﹤0.01% 3229
2021
Q4 		$23.6M Buy
1,137,705
+25,572
+2% +$816K ﹤0.01% 3177
2021
Q3 		$38.9M Buy
1,112,133
+66,499
+6% +$2.87M ﹤0.01% 2830
2021
Q2 		$54.1M Buy
+1,045,634
New +$54.9M ﹤0.01% 2645

Other funds holding DFTX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

BlackRock's DFTX Position: Q1 2026 in Review

BlackRock increased its Definium Therapeutics (DFTX) stake by 2.5% in Q1 2026, buying an estimated $3.51M and bringing the position to 8,480,230 shares worth $160M. The position accounts for ﹤0.01% of the portfolio, ranked #1803.

BlackRock first reported a position in DFTX in Q2 2021 and has held it in 20 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • BlackRock held 8,480,230 shares of Definium Therapeutics worth $160M as of Q1 2026.
  • BlackRock bought 206,954 Definium Therapeutics shares in Q1 2026, an estimated $3.51M.
  • Definium Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #1803 holding.
  • BlackRock first reported a position in Definium Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.